Belgium-based brain imaging AI company icometrix announced it received a CPT III code from the American Medical Association enabling reimbursement of its FDA-cleared brain MRI quantification software.
icometrix AI-supported quantitative brain analysis software provides metrics for cerebral MRI scans to help clinicians diagnose, monitor and evaluate treatment responses in patients with neurological conditions, such as Alzheimer's disease and dementia, multiple sclerosis, epilepsy, stroke and Parkinson's disease.
The CPT code will allow qualified healthcare professionals to report their use of icometrix brain imaging AI software as a practice expense.
THE LARGER TREND
icometrix received $18 million in funding in 2019 to grow its brain software. The Belgium company garnered FDA clearance for its icobrain-ctp offering in February 2020.
Last month, the company announced it was awarded a grant from the Michael J. Fox Foundation to research brain MRI biomarkers for Parkinson's disease in collaboration with a neurology and neurological sciences professor at Stanford Medicine.
Another company using AI software to help providers diagnose brain disorders is South Korean health tech company Neurophet. In April, it obtained certification from Singapore's Health Sciences Authority for its AI-enabled degenerative brain disease diagnosis assistant software.
Tags: icometrix, AI imaging, brain imaging, AI analysis
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.